Skip to content
Adiposs SA

Adiposs | Raised CHF 1.8M 1st closing of its Pre-Series A round

Share this article

CHF 1.8M to start clinical trials & product industrialisation


Adiposs SA, the developer of a unique diagnostic product for the non-invasive early detection of body wasting-cachexia, announced a CHF 1.8M first closing of its Pre-Series A round. The round was led by Privilège Ventures, a Swiss-based venture capital firm focused on seed and early-stage investments. Other investors include CR Ventures (CRV), Kick Foundation (Venture Kick), Fondation Genevoise pour l’Innovation Technologique (Fongit), a Singapore-based family office (Kingbridge), and a group of business angels.

The investment round will be used to manufacture the first batch of ImageBAT, a first-in-class contrast agent for brown adipose tissue detection, as well as to perform the first-in-human clinical trial. 


About Adiposs

Co-founders Andrej Babic, Justyna Plewka and Nathalie Stransky-Heilkron, and the Adiposs, team are developing a game-changing product called ImageBAT. It’s the first product that can detect body wasting in cancer and chronic disease patients before irreversible weight loss, and when treatments are still effective. ImageBAT-enhanced medical scan is fast, pain-free and will be available in every hospital worldwide. By making body wasting visible early, Adiposs enables early treatment for millions of patients, giving them better and longer lives.


Press Release